

March 5, 2019

William T. Schmidt  
President and CEO

Gregory P. Cosgrove, MD  
Chief Medical Officer

### Senior Medical Staff

Pauline Bianchi, RN  
Harold Collard, MD  
Kevin R. Flaherty, MD, MS  
David Lederer, MD

### Medical Advisory Board

Andrew H. Limper, MD, Chair  
Joseph A. Lasky, MD, Chair,  
Scientific Advisory Council

Timothy S. Blackwell, MD  
Kevin K. Brown, MD  
Jeffrey T. Chapman, MD  
Rany Condos, MD  
Aryeh Fischer, MD  
Christine Kim Garcia, MD, PhD  
Andreas Günther, MD  
Susan S. Jacobs, RN, MS  
Naftali Kaminski, MD  
David W. Kamp, MD  
Martin Kolb, MD  
Kathleen O. Lindell, PhD, RN  
James E. Loyd, MD  
David A. Lynch, MD  
Fernando J. Martinez, MD, MS  
Imre Noth, MD  
Ralph J. Panos, MD  
Ganesh Raghu, MD  
Luca Richeldi, MD, PhD  
Jesse Roman, MD  
David A. Schwartz, MD  
Marvin I. Schwarz, MD  
Moisés Selman, MD  
Patricia J. Sime, MD  
Charlie Strange III, MD  
Jeffrey James Swigris, DO, MS  
Janet Talbert, MS, CGC  
Eric White, MD

## AN UPDATE OF STEM CELL/CELL-BASED THERAPIES FOR PULMONARY FIBROSIS BEYOND THE CONTEXT OF CLINICAL TRIALS: A word of caution by the Medical Advisory Board of the Pulmonary Fibrosis Foundation (PFF).

To members of the Pulmonary Fibrosis Community,

### Summary Statement

We want to update you on the status of stem cell therapies for the treatment of pulmonary fibrosis. While studies continue to evaluate the potential use of these treatments, there are currently no studies proving that they are helpful. Considering the information available, **we strongly recommend that patients not engage in such treatments outside of an approved clinical trial.**


As part of a clinical trial:

- There are no costs or fees associated with participation
  - The cost of the clinical trial is paid for by drug developers or governmental agencies
- Written informed consent is required
- Decisions are based on a research protocol
- It is designed and intended to benefit **future** patients
- There are periodic and systematic assessment of patient data
- The study is protected by government agencies, institutional review adherence to professional and legal standards

More detailed information about clinical trials can be obtained from the PFF website ([pulmonaryfibrosis.org](https://pulmonaryfibrosis.org)) and specific clinical trials evaluating innovative therapies can be identified using the PFF Clinical Trial Finder (<https://trials.pulmonaryfibrosis.org>).

Patients, relatives, advocacy experts, industry, physicians, researchers, and federal agencies contributed to the prior successes and are essential for further advances. The entire PF community is responsible for this continued progress and our work will continue as we imagine a world without PF.

On behalf of the Pulmonary Fibrosis Foundation Medical Advisory Board,



William T. Schmidt



Gregory P. Cosgrove,  
Chief Medical Officer




Andrew Limper, MD  
Chair, Medical Advisory Board



Joseph Lasky, MD  
Chair, Scientific  
Advisory Council



Eric S. White, MD, MS  
Medical Advisory Board



Marilyn K. Glassberg, MD